The UK National Institute for Health and Care Excellence (NICE) has granted approval for Roche’s breast cancer drug Kadcyla for routine use within the NHS region. NICE has recommended Kadcyla
Tag "Roche"
Roche’s oral ALK inhibitor, Alecensa, has been conditionally approved in the European Union as a monotherapy for anaplastic lymphoma kinase-positive advanced non-small cell lung cancer (NSCLC) in adults who were
Roche’a anticipated approval of ocrelizumab will drive the company’s share of the market from <1% in 2016 to 15% by 2022, according to GBI Research The company’s report states that
Advertisements
